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Abstract
Objectives/background: Given the widespread prevalence of micronutrient deficiencies in developing countries,
supplementation with multiple micronutrients rather than iron-folate alone, could be of potential benefit to the
mother and the fetus. These benefits could relate to prevention of maternal complications and reduction in other
adverse pregnancy outcomes such as small-for-gestational age (SGA) births, low birth weight, stillbirths, perinatal
and neonatal mortality. This review evaluates the evidence of the impact of multiple micronutrient supplements
during pregnancy, in comparison with standard iron-folate supplements, on specific maternal and pregnancy
outcomes of relevance to the Lives Saved Tool (LiST).
Data sources/review methods: A systematic review of randomized controlled trials was conducted. Search
engines used were PubMed, the Cochrane Library, the WHO regional databases and hand search of bibliographies.
A standardized data abstraction and Child Health Epidemiology Reference (CHERG) adaptation of the Grading of
Recommendations Assessment, Development and Evaluation (GRADE) technique were used for data abstraction
and overall quality of evidence. Meta-analyses were performed to calculate summary estimates of utility to the LiST
model for the specified outcome of incidence of SGA births. We also evaluated the potential impact of multiple
micronutrients on neonatal mortality according to the proportion of deliveries occurring in facilities (using a
threshold of 60% to indicate functionality of health systems for skilled births).
Results: We included 17 studies for detailed data abstraction. There was no significant benefit of multiple
micronutrients as compared to iron folate on maternal anemia in third trimester [Relative risk (RR) = 1.03; 95%
confidence interval (CI): 0.87 – 1.22 (random model)]. Our analysis, however, showed a significant reduction in SGA
by 9% [RR = 0.91; 95% CI: 0.86 – 0.96 (fixed model)]. In the fixed model, the SGA outcome remained significant
only in women with mean body mass index (BMI) ≥ 22 kg/m
2. There was an increased risk of neonatal mortality in
studies with majority of births at home [RR = 1.47, 95% CI: 1.13-1.92]; such an effect was not evident where ≥ 60%
of births occurred in facility settings [RR = 0.94, 95% CI: 0.81-1.09]. Overall there was no increase in the risk of
neonatal mortality [RR = 1.05, 95% CI: 0.92 – 1.19 (fixed model)].
Conclusion: This review provides evidence of a significant benefit of MMN supplementation during pregnancy on
reducing SGA births as compared to iron-folate, with no significant increase in the risk of neonatal mortality in
populations where skilled birth care is available and majority of births take place in facilities. Given comparability of
impacts on maternal anemia, the decision to replace iron-folate with multiple micronutrients during pregnancy
may be taken in the context of available services in health systems and birth outcomes monitored.
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Low birth weight, small-for-gestational age (SGA), pre-
term birth, stillbirths, perinatal and neonatal mortality
are important adverse outcomes of pregnancy [1]. The
incidence of low birth weight in developing countries
varies from 6 - 30%, and at least one-third of these are
small for gestational age, especially in settings with high
rates of maternal undernutrition. Small for gestational
age (SGA) babies are those whose birth weight lies below
the 10
th percentile for a particular gestational age [2].
Vast majority of these are due to fetal growth problems
that occur during pregnancy, including intrauterine
growth restriction (IUGR) [3]. Full term SGA infants may
not have complications related to organ immaturity like
those of pre-term infants of similar size, but are at an
increased risk of stillbirth and perinatal/neonatal mortal-
ity due to perinatal asphyxia, meconium aspiration and
hypoglycaemia [4,5]. Women of reproductive age, espe-
cially pregnant women, in developing countries are
recognized to be at risk of multiple micronutrient defi-
ciencies, such as iron, folic acid, iodine, zinc, vitamins A
and D, riboflavin, B6 and B12, with the likelihood of
adverse effects on the mother and pregnancy outcomes
[1,6]. Pregnancy represents a state of increased metabolic
requirements, and intake of key micronutrients by preg-
nant women especially in developing countries is usually
inadequate. This inadequate intake and increased
requirement further exacerbates the pre-existing mater-
nal deficiency [7].
Iron deficiency contributes to one of the largest preva-
lence of micronutrient deficiencies among pregnant
women. For example, anaemia affects approximately
41.8% of all pregnancies globally [8], with iron deficiency
accounting for half of the cases [9]. Retrospective and
observational studies have demonstrated a higher risk of
maternal mortality in severely anaemic pregnant
women, predisposing to death from haemorrhage and
infections. Maternal iron deficiency anaemia also has
adverse effects on birth outcomes including a greater
risk of birth asphyxia, low birth weight, preterm delivery
and lower Apgar scores [10,11]. The association of
maternal anemia with adverse outcomes is largely based
on observational studies and risk assessment [12] and
objective evidence that iron-folate supplementation in
pregnancy improves outcomes other than anemia is not
well established.
Given the significant impact of deficiencies of key
micronutrients during pregnancy [6], supplementation
with multiple micronutrients during pregnancy may be a
feasible public health strategy. One potential advantage
of multiple micronutrients could be that they might have
comparable benefits to iron-folate in reducing anemia,
and could also have additional benefits on intrauterine
growth and outcomes in the neonatal period and infancy
[7]. Many workers had attempted augmentation of iron-
folate supplementation in pregnancy with additional
micronutrients, but the first systematic efforts to under-
take this were almost a decade ago [7]. In 1999 the
UNICEF/WHO/UN University proposed a prenatal sup-
plement UNIMAPP containing fifteen micronutrients,
including iron and folic acid which could provide one
recommended daily allowance of each and potentially
replace standard iron-folate supplements for pregnant
women in low and middle income countries [13]. It was
speculated that a combination of more than one micro-
nutrient may have additive and/or synergistic benefit on
maternal and child outcomes. Systematic information on
the benefits if any, of such supplements in improving
maternal and pregnancy outcomes is, however, limited.
A Cochrane review on the subject in 2006 [14] indicated
that compared to iron-folate, multiple micronutrient sup-
plementation (defined as administration of three or more
micronutrients), did not have any significant benefits on
maternal anemia (data from one study) and prevalence of
SGA births (data included from 2 studies). Another sys-
tematic review was undertaken by a team commissioned
by UNICEF/WHO/SCN which analysed data from 12
trials using the UNIMAPP formulation and evaluated
effects on maternal and pregnancy outcomes [15] There
have been concerns regarding increased risk of perinatal
and neonatal mortality with multiple micronutrient sup-
plementation through increased birth asphyxia in heavier
babies [9] In this paper, we included additional studies
since the Cochrane review in 2006 and have evaluated
the evidence of the potential impact of multiple micronu-
trient supplementation in pregnancy on the maternal and
pregnancy outcomes using Child Health Epidemiology
Reference Group (CHERG) rules [16]. Given that the
Lives Saved Tool (LiST) largely models SGA outcomes
for potential maternal nutrition interventions, we specifi-
cally focused our analysis to evaluate the impact of
maternal multiple micronutrient interventions on risk of
delivering SGA infants and also evaluated the impact on
neonatal mortality.
Methods
Searching
We evaluated all relevant literature on maternal multiple
micronutrient supplementation during pregnancy for
assessment of effects on pregnancy outcomes, up to
December 2009. The databases searched included
PubMed, the Cochrane Systematic Reviews, the World
Health Organization Regional Databases and hand
search of bibliographies of relevant reviews. Experts
were also contacted in the field for unpublished data.
The basic search strategy used was:
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OR maternal OR pregnancy) AND (“Micronutrients”[-
Mesh] OR “multiple micronutrient*” OR multivitamin
OR micronutrient*) AND (supplement*)
Selection (inclusion/exclusion criteria)
All prospective randomized controlled trials (RCTs) eval-
uating multiple micronutrient supplementation in
women during pregnancy, irrespective of language or
publication status, were included. Multiple micronutri-
ents were defined as supplementation with at least 5
micronutrients including the UNIMMAP formulation
[13] or those with comparable composition. These sup-
plements were compared to maternal iron-folate supple-
mentation. There were no limits on gestational age at the
time of enrolment in the study and the duration of sup-
plementation. Quasi-randomized trials were excluded as
there was an adequate number of good quality RCTs
available. We did not conduct sub-group analyses with
respect to different dosages of iron in the multiple micro-
nutrient supplements. Other than the assessment of SGA
and neonatal mortality, we did not specifically evaluate
minor adverse effects of the supplements such as nausea
and vomiting among the mothers and newborns.
Validity assessment
The overall quality of evidence of an outcome, however,
was assessed and graded according to the CHERG adap-
tation of the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) technique [16,17]
based on three components: 1) the volume and consis-
tency of the evidence; 2) the size of the effect, or risk
ratio; and 3) the strength of the statistical evidence for an
association between the intervention and outcome, as
reflected by the p-value [16]. The individual studies were
also graded. Three categories of criteria were used to
judge quality of individual study evidence in the meta-
analysis: 1) study design; 2) study quality; 3) relevance to
the objectives of the review [16]. The following four
grades were given to individual studies: high, moderate,
low or very low. Study received an initial score of high if
it was a randomized or cluster randomized trial. The
grade was decreased by 0.5 to 1 for each study design
limitation. In addition, studies reporting an intent-to-
treat analysis or with statistically significant strong levels
of association (>80% reduction) received 0.5-1 grade
increases. Any study with a final grade of very low was
excluded on the basis of inadequate study quality. This
review is shaped in large part by the needs of the LiST
model. In that model, increases in coverage of an inter-
vention result in a reduction of one or more cause-speci-
fic deaths or in reduction of a risk factor. Therefore, this
review and the grade process used are designed to
develop estimates of the effect of an intervention in
reducing either a risk factor or a death due to specific
cause. For more details of the review methods, the
adapted grade approach or the LiST model, see the
CHERG method’s paper [16]. For the LiST tool, we have
defined SGA as an outcome rather than low birth weight
as the model utilizes the former for the cohort effect.
The SGA babies, belonging to the least 10
th centile of the
birth weight, would be at a higher risk of mortality and
thus a greater effect of any intervention. Besides, in
several populations used in the studies, the two terms
have been used synonymously.
Data abstraction and study characteristics
Each study that satisfied the eligibility criteria was
included in the review. Data were double abstracted into
a standardized rectangular database [16] that was acces-
sible through Excel (Additional File 1). Key variables
like participants’ characteristics, sample size, location,
setting, blinding, allocation concealment, description of
intervention and control groups (in terms of dosage and
time of enrolment) and all the other outcomes of inter-
est were recorded.
Quantitative data synthesis
The assessment of statistical heterogeneity among trials
was done by visual inspection i.e. the overlap of the con-
fidence intervals among the studies, and by the Chi
square (P-value) of heterogeneity in the meta-analyses.
A low P value (less than 0.10) or a large chi-squared sta-
tistic relative to its degree of freedom was considered as
providing evidence of heterogeneity. The I
2 values were
also looked into, and roughly an I
2 greater than 50%
was taken to represent substantial and high heterogene-
ity. In situations of substantial or high heterogeneity
b e i n gp r e s e n t ,c a u s e sw e r ee x p l o r e d ,s u b - g r o u pa n a l y s e s
performed and random effects model was used and
although, this random model is not a substitute for a
thorough investigation of heterogeneity, it was primarily
to take into account heterogeneity that could not be
explained [18]. Pooled estimates were generated by gen-
eric inverse variance method of meta-analysis using
Review Manager (version 5) software. For all cluster ran-
domized trials, cluster adjusted estimates were used. For
the purpose of the analyses of the studies with factorial
designs, we have assumed that there was no interaction
between other interventions and the effect of supple-
mentation, since all interventions were randomized.
Results are presented as risk ratios (RR) and corre-
sponding 95% confidence intervals (CI). We summarized
evidence of the outcomes including qualitative grading
of the study quality and quantitative attributes according
to the reference guidelines [16]. The CHERG Rules for
Evidence Review were applied to the outcomes of SGA
and neonatal mortality. For SGA, sub-group analyses
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mass index (BMI). In an effort to understand the con-
text of neonatal outcomes, wee v a l u a t e dt h ee f f e c to f
multiple micronutrient supplements on neonatal mortal-
ity by sub-group analysis according to the percentage of
facility based deliveries. Not all studies provided suffi-
cient data to allow categorization of health system func-
tionality for maternal health, but information on facility
births or home births was available. We used an arbi-
trary cut off of 60%, where more than 60% facility births
represented a proxy for skilled attendance.
Results
Trial flow
A total of 4,187 hits were identified from our search
strategy (Figure 1). After screening the titles and
abstracts, 43 studies were initially considered eligible
and finally, 17 studies comprising of 14 trials were
selected for inclusion in this review. We evaluated the
impact of the intervention on the following outcomes:
maternal anemia, SGA and neonatal and early infant
mortality.
Study characteristics
The baseline characteristics of all the studies including
the location, sample size, type of participants, interven-
tion composition and limitations are given in Additional
File 2. Six out of fourteen included studies had used
cluster randomized design [19-26]. All studies were
from low-/middle-income settings. Some of the studies
had limitations based on study design and execution
such as large losses to follow-up, insufficient power to
detect differences in SGA and mortality, and missing
compliance data. Twelve studies used multiple micronu-
trient supplement formula called UNIMMAP which
consisted of 30 mg iron, 400 µg folic acid, 15 mg zinc,
Number of studies identified  
(n =   4187) 
Records screened  
(n = 4187) 
Records excluded  
(n = 4144) 
Full-text articles excluded  
(n = 26) 
Full-text articles assessed for 
eligibility (n = 43) 
Studies included in the 
review 
 (n = 17) 
Maternal 
anaemia=4  
Neonatal
mortality=9
Small for gestational 
age=14
Figure 1 Flow diagram showing identification of studies.
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Page 4 of 92 mg copper, 65 µg selenium, 800 µg RE vitamin A, 1.4
mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9
mg vitamin B6, 2.6 µg vitamin B12, 70 mg vitamin C,
5 µg vitamin D, 10 mg vitamin E and 150 µg iodine.
The formulas used in rest of the studies were compar-
able to UNIMMAP except in small variation in dose of
iron and folic acid used. Additional File 3 presents the
risk of bias in all studies in accordance with the latest
recommendations of the Cochrane Handbook [18].
Quantitative data synthesis
Table 1 reports the overall quality grading of the out-
c o m e sa n dr e s u l t so ft h ec o r r esponding meta-analyses.
The minimum number of micronutrients in the studies
was nine. In most studies, the comparison (control) sup-
plement was composed of 60 mg of iron and 400 µg of
folic acid. The UNIMAPP formulation containing 30 mg
iron and 0.4 mg folic acid was provided in nine trials
[19-22,24,27-30]. In study by Friis et al. [31], iron-folate
was not part of the intervention composition and iron-
folate tablets were provided separately as part of routine
antenatal care. The intervention group in the Fawzi et
al. study [32] received multiple micronutrient tablets
containing 0.8 mg of folic acid along with separate iron
and folic acid supplementation. In the study by Gupta et
al. [33], the multi-micronutrient tablet contained 10 mg
of ferrous fumarate and 0.15 mg of folic acid along with
supplemental iron-folate. The composition of interven-
tion in the study by Christian et al. study [23,25,26]
included 60 mg iron and 0.4 mg folic acid, while
Ramakrishnan et al. [34,35] provided 62.4 mg iron and
0.215 mg folic acid in the multi-micronutrient
formulation.
Multiple micronutrient supplementation had no signifi-
cant effect on maternal anemia in the third trimester com-
pared to iron-folate based on data from 4 RCTs (RR =
1.03; 95% CI: 0.87 – 1.22; random model) [22,25,28,35]
(Additional File 4). There was a statistically significant 9%
reduction in the risk of small for gestational age infants
with multiple micronutrient supplements (RR = 0.91; 95%
CI: 0.86 – 0.96; fixed model) based on fourteen studies
[19-24,27-34] (Additional File 5A). These results also
remained significant with the random effects model (RR =
0.88; 95% CI: 0.81 – 0.95) (Additional File 5B). The sub-
group analysis used a cut-off of mean maternal BMI of
22 kg/m
2. The intervention effect relative to the control
group in the fixed model was significant only for women
with mean BMI greater than or equal to 22 kg/m
2 (RR =
0.89, 95% CI: 0.83 – 0.95), but significant for both the sub-
groups in the random model.
Our pooled estimates did not show a statistically signifi-
cant increase in the risk of neonatal mortality based on
nine RCTs [19,21,22,24,26-30] in both the fixed (RR =
1.05; 95% CI: 0.92 – 1.19) (Additional File 6A) and ran-
dom effect models (RR = 1.17; 95% CI: 0.95 – 1.44)
(Additional File 6B). We also performed a sub-group
analysis for neonatal mortality with respect to the per-
centage of facility-based deliveries. This was determined
from the information provided in the study, or from the
general information on the study location. There was an
Table 1 Quality assessment of trials of multiple micronutrient supplementation for maternal and pregnancy outcomes
(Multiple micronutrients versus iron folate)
Quality Assessment Summary of Findings
Directness No of events
No of
studies
(ref)
Design Limitations Consistency Generalizability
to population
of interest
Generalizability
to intervention
of interest
Intervention Control Relative Risk
(95% CI)
Maternal Anaemia: Highoutcome specific quality
4 cRCT/
RCT
Some – high loss to
follow-up and inadequate
power (-0.5)
Heterogeneity in
the meta-analysis
= 50%. 2/4
studies showing
benefit (-0.5)
All in developing
countries
Generalizable 351 336 1.03 (0.87 - 1.22),
random model
a
Small-for-gestational age: Highoutcome specific quality
14 cRCT/
RCT
Some – high loss to
follow-up, inadequate
power, missing data
(compliance), one study
with a co-intervention
(-0.5)
Consistent with
13/14 studies
showing benefit
All in developing
countries
Generalizable 2289 2494 0.91 (0.86, 0.96),
fixed model
a
Neonatal mortality:Highoutcome specific quality
9 cRCT/
RCT
Some - inadequate power
of the studies (-0.5)
7/9 studies
giving a risk ratio
of greater than 1
All in developing
countries
Generalizable 558 513 1.05 (0.92, 1.19),
fixed model
a
a = generic inverse variance.
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majority of births at home [RR 1.47, 95% CI 1.13-1.92];
such an effect was not evident where ≥ 60% of births
occurred in facility settings [RR 0.94, 95% CI 0.81-1.09].
Discussion
Our evaluation of multiple micronutrient supplements
during pregnancy did not show a significant benefit of
the supplement on maternal anaemia in third trimester
as compared to iron-folate. These findings corroborates
those from earlier reviews [14,36] which also revealed
no significant benefit of multiple micronutrients over
iron-folate. However, our review does indicate that mul-
tiple micronutrient administration is associated with a
significant reduction in SGA births in comparison with
iron-folate administration (9% and 12% reduction in the
fixed and random effects models, respectively). These
findings are comparable to the results of the systematic
review of UNIMAPP trials [37] (pooled OR = 0.90; 95%
CI: 0.82 – 0.99) based on 12 studies, which are also
included in our analysis. These findings are however,
different from our previous Cochrane review which was
based on a limited set of studies [14] and reported a
non-significant effect on SGA (RR = 1.04; 95% CI: 0.93
– 1.17). Our current data are also at variance with a
recent meta-analysis by Shah et al. [38] which analyzed
results from only 5 RCTs and reported a statistically
insignificant impact on SGA (RR = 0.89; 95% CI: 0.77 –
1.01). In our current review, 13 out of 14 studies
showed consistent results with respect to SGA babies
i.e. a risk ratio of less than 1. The study by Christian
et al. reported a risk ratio of greater than 1, but was sta-
tistically not significant (RR = 1.04; 95% CI: 0.94 – 1.15)
[23]. The overall quality of evidence for this outcome
was high, with a strong statistical association with the
P-value of 0.0002 in the fixed model. Given that the
LiST model uses the impact pathway via SGA, we are
recommending a point estimate of 9% reduction in SGA
for inclusion in the LiST tool for situations where coun-
tries may decide to replace routinely used iron-folate
supplements during pregnancy with multiple micronu-
trients. The sub-group analysis with respect to maternal
BMI showed that there was a significant reduction in
S G Ao n l yi nm o t h e r sw h o s em e a nb a s e l i n eB M Iw a s≥
22 kg/m
2, and the result was non-significant for BMI
less than this. It is difficult to explain these findings as
it may in part be an artefact caused by the way mothers’
BMI status were determined. It should to be noted
that weight gain in pregnancy is not linear, and women
who entered early in the study would be classified as
thin compared to those who entered the study in the
later stages. Another possible explanations could be
hypothesized like decreased ability of malnourished
mother to utilize multiple nutrients [39]. However a
trial conducted in India on malnourished women did
not support this hypothesis [33]. Certain other factors
that need to be considered are the age of the mother,
composition of multiple micronutrient supplement and
co-supplementation of macronutrient like balanced pro-
tein energy supplementation [40].
There is considerable debate on the potential adverse
effects of providing multiple micronutrient supplements
during pregnancy with a concern about an increase in
neonatal mortality in less developed health systems that
have suboptimal maternal care [41,42]. There are a few
studies that reported mortality beyond the neonatal per-
iod with maternal multiple micronutrient supplementa-
tion, the data of which has not been pooled. Christian
et al. [26] had reported infant deaths (0 – 3m o n t h s )i n
the multiple micronutrient recipients versus controls
(receiving vitamin A only) with a non-significant higher
risk in the micronutrient group (RR = 1.07; 95% CI:
0.75 – 1.58). In contrast, Shankar et al. [21] in the consid-
erably larger SUMMIT trial, reported a statistically signif-
icant 18% reduction in early infant mortality (0 –
3 months) in the multiple micronutrient group compared
to iron-folate (RR = 0.82; 95% CI: 0.70 – 0.95; P = 0.010),
with comparable results for post-neonatal mortality –
from 29 days to 90 days after birth (RR = 0.70; 95% CI:
0.55 – 0.89). Our analysis of data from nine studies
showed a non-significant effect on neonatal mortality
(fixed effects: RR = 1.05; 95% CI: 0.92 – 1.19; random
effects: RR = 1.17; 95% CI: 0.95 – 1.44). There was evi-
dence that this risk might be related to the provision of
skilled deliveries and standard of care in the health sys-
tem. The 4 intervention trials conducted in populations
where the majority of births occurred at home were asso-
ciated with significant increase in the risk of neonatal
mortality. However, this effect was not seen in the other
5 settings where the majority of births were in facilities.
These results are generally consistent with a UNIMAPP
trials analysis [43] with a notable, though non-significant
increase in early neonatal mortality (OR = 1.23; 95% CI:
0.96 – 1.59), while there was a 6% non-significant reduc-
tion in late neonatal mortality (OR = 0.94; 95% CI: 0.73 –
1.23). These findings suggest that the use of multiple
micronutrient supplements in populations to address
maternal anemia and reduce the incidence of SGA, must
be accompanied by the provision of skilled care at deliv-
ery and facility births to offset any potential increase in
the risk of obstructed labour and birth asphyxia [44,45].
It must be noted that in most studies evaluated, despite
reduction in rates of SGA, there was no reduction in neo-
natal mortality. A review of the relationship between
IUGR and neonatal mortality largely based on observa-
tional studies did not distinguish if the effects on neona-
tal mortality were mediated through IUGR or other
concurrent factors [5]. Applying the CHERG Rules for
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mortality outcomes as high grade of evidence. Included
studies had some minor limitations, especially insufficient
power to detect differences in mortality between the
groups. The studies, in general, were representative of
the low-income populations. However, caution must be
exercised in adapting the findings of multiple micronutri-
ent supplements to programs without further effective-
ness trials and robust evaluation in health systems.
It is surprising to note that the participants remained
anemic in the included studies, even though they were
taking seemingly adequate amounts of supplemental
iron. There is no exact reason for this but this has been
seen in many effectiveness trials over the years [40]. An
important aspect to consider is the timing of initiation
of multiple micronutrient supplements. Starting the sup-
plementation during pregnancy may be too late for
many women, especially those with pre-existing anemia
[40]. Berger et al. from Vietnam had reported that the
pre-pregnancy use of weekly iron–folic acid is associated
with better iron status in the first and second trimesters
and with reduced prevalence of LBW compared with
pregnant women who only received daily iron–folic acid
supplementation during pregnancy [46]. Another reason
could be the amount of iron in the supplement, as
higher dosages may be associated with more side effects
of diarrhea and thus less absorption [40,47]. Similarly
one possible reason could be infections, since these
were not systematically treated across the trials. World
health organization recommends the treatment of infec-
tions (especially deworming) for control of anemia along
with supplementation of iron [48].
The observed benefit of multiple micronutrients in the
SUMMIT trial [21] on early infant and post-neonatal
mortality opens the interesting possibility that such
intrauterine supplements may benefit infants beyond the
neonatal period. This is further corroborated by the
improved growth beyond infancy noted among recipi-
ents of maternal micronutrient supplements in Nepal
[49]. Given the multiple effects of micronutrients in the
regulation of body metabolism and growth [21], these
effects are biologically plausible but need further evalua-
tion with a range of additional outcomes, including
child development indicators.
While there have also been calls for greater evaluation
of potential interactions between various micronutrients
[50], we feel that the field is ripe for well conducted
effectiveness trials in health systems. The overall results
of maternal micronutrient supplements call for further
carefully conducted demonstration projects in health
systems with adequate monitoring of pregnancy out-
comes. Such studies may also overcome several of the
limitations of size and power in the currently available
literature. It must be underscored that intake of multivi-
tamins and micronutrients are almost universal during
pregnancy in developed countries and among the rich in
developing countries [51]. Policy makers in health sys-
tems with adequate provision of skilled care may choose
to introduce multiple micronutrient supplements in lieu
of routine iron-folate for pregnant women with adequate
monitoring and evaluation.
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